Exhaled carbon monoxide in asthmatic adults with bronchial reactivity: a prospective study.

HYPOTHESIS: We hypothesized that eCO may permit non-invasive assessment of disease activity in adults with asthma and bronchial reactivity. METHODS: A total of 209 participants 18 to 65 years of age with a diagnosis of asthma and bronchial reactivity provided data for analysis. The association between eCO and bronchial reactivity, forced expiratory volume in one second (FEV(1)), forced vital capacity (FVC), peak expiratory flow rate measurements (PEFR), asthma symptoms score, and bronchodilator use cross-sectionally and within-subject change in eCO were analyzed in relation to change in these variables over 6 weeks. RESULTS: There was no difference in eCO in those who were taking inhaled corticosteroids and those who were not (p = 0.33). There was also no cross-sectional or within-in subject association between eCO and bronchial reactivity, FEV(1), FVC, PEFR, symptoms score, or bronchodilator use. CONCLUSIONS: In a population of adults with bronchial reactivity, eCO has no or very limited potential as a biomarker of asthma activity.

Does a low sodium diet modify heart rate variability? A randomised placebo-controlled double-blind trial.

BACKGROUND: Increased heart rate variability (HRV) is associated with a low risk of mortality, as is consuming a low sodium diet. As the survival benefits of a low sodium diet may be mediated partly by an increase in HRV, we have tested the hypothesis that adopting a low sodium diet increases HRV. METHODS: We used a randomised double-blind placebo-controlled trial design. Participants were aged 18-65 years old, had a physician diagnosis of asthma. All adopted a low sodium diet and they were randomised to receive either 80 mmol/day of oral sodium supplements (normal sodium intake - NSI) or matched placebo (low sodium intake-LSI) for 6 weeks. The primary outcome was change in SDNN (standard deviation of the N-N intervals); secondary outcomes were changes in other time domain and frequency domain measures of HRV. RESULTS: In those allocated to the LSI, mean daily urinary sodium excretion decreased by 22 mmol; and in those allocated to the NSI mean daily urinary sodium excretion increased by 31 mmol. There were no differences between the two groups for either the primary or secondary outcome measures. The mean difference in change in SDNN between those who received the LSI compared to the NSI was -2.7 ms (95% Confidence Intervals CI; -18.0 to +12.6). CONCLUSIONS: Adopting a low sodium diet does not have an impact on SDNN over a 6 weeks period. Future studies should aim to achieve a larger change in dietary sodium intake for a longer duration than 6 weeks.

Does a low sodium diet improve asthma control? A randomized controlled trial.

RATIONALE: Observational studies and initial randomized trials have indicated that a low sodium diet may improve asthma control. OBJECTIVES: We tested the hypothesis that a low sodium diet would improve asthma control over a 6-week period. METHODS: Participants with a physician diagnosis of asthma and measurable bronchial reactivity to methacholine entered a randomized double-blind placebo-controlled trial. All adopted a low sodium diet and were randomized to receive either 80 mmol/day of oral sodium supplements (normal sodium intake) or matched placebo (low sodium intake) for 6 weeks. The primary outcome was change in bronchial reactivity to methacholine; secondary outcomes were change in lung function, morning and evening peak expiratory flow, asthma symptoms score, daily bronchodilator use, Juniper Standardized Asthma Quality of Life Questionnaire score, and atopy. MEASUREMENTS AND MAIN RESULTS: A total of 220 individuals entered the study, of whom 199 completed the protocol. In the low sodium-intake group, mean daily urinary sodium excretion decreased by 20 mmol (SD, 64 mmol) and in the normal-sodium-intake group increased by 28 mmol (SD, 74 mmol). There were no differences between the two groups in the primary or secondary outcome measures; the mean difference in bronchial reactivity between the low- and normal-intake groups was -0.03 doubling doses of methacholine (95% confidence interval, -0.60 to 0.53). CONCLUSIONS: The use of a low sodium diet as an adjunctive therapy to normal treatment has no additional therapeutic benefit in adults with asthma and bronchial reactivity to methacholine.